Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

  title={Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential},
  author={James J. H. Rucker},
  journal={BMJ : British Medical Journal},
  • J. Rucker
  • Published 26 May 2015
  • Psychology
  • BMJ : British Medical Journal
Trials of physiologically safe and non-addictive drugs such as LSD are almost impossible, writes James J H Rucker, calling on the authorities to downgrade their unnecessarily restrictive class A, schedule 1 classification 
Changes Need To Be Made To Make Research More Feasible on Scheduled Drugs for Recreational Purposes as Well
  • J. Brenner
  • Psychology
    The American journal of bioethics : AJOB
  • 2016
It is suggested that marijuana has medicinal purposes, and has been shown to be effective for managing debilitating pain, nausea, and vomiting associated with chemotherapy, decreasin and other diseases.
Psychedelics: Old drugs, new trips
This special edition of the Journal of Psychopharmacology continues a reflection of psychopharmacological’s vogue to breathe new life into old drugs, with a characterisation of the relevance of the 5-HT2A receptor to the psychedelic state, and a study of the neural and subjective effects of a short acting psychedelic.
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years.
Apotential role for psilocybin in the treatment of obsessive-compulsive disorder
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.
Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?
Three articles rise the fundamental question of mechanism behind therapeutic effects of hallucinogenic and entactogenic substances, which patients might benefit from these treatments and which might not, how therapeutic effects can be promoted and risks further minimized.
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
A public-health-based model for the regulation of psychedelics is described, which includes governance, supervision, set and setting controls, youth access, supply control, demand limitation, and evaluation.
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
The evidence to date is strongest for the use of LSD in the treatment of alcoholism, and new studies that conform to modern standards are necessary in order to strengthen knowledge on its use and open new doors in the future.
The link between use of psychedelic drugs and mental health problems
It is argued that the authors’ conclusions in their latest paper are not substantiated by their results and will propose supplemental analyses to validate or potentially revise their conclusions.
Back to the future: Research renewed on the clinical utility of psychedelic drugs
The use of psilocybin in the treatment of depression and anxiety in cancer patients and a substantial therapeutic effect of two drug administrations in a crossover design on the target symptoms of anxiety and depression in a heterogeneous group of cancer patients with comorbid psychopathology are described.
Global bioethical challenges of medicalising psychedelics
Psychedelic-assisted psychotherapy is an emerging psychiatric treatment that is attracting significant scientific, medical, and public attention. Whilst preliminary results from empirical studies


Effects of Schedule I drug laws on neuroscience research and treatment innovation
An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses difficult and in many cases almost impossible.
  • R. Strassman
  • Psychology, Medicine
    The Journal of nervous and mental disease
  • 1984
The basic pharmacology of the major synthetic psychedelic compounds (primarily lysergic acid diethylamide [LSD]-25) is described and reference is made to their potentially beneficial psychological effects.
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Psychedelics and Mental Health: A Population Study
It was found that in several cases psychedelic use was associated with lower rate of mental health problems, and use of psychedelics was not found to be an independent risk factor formental health problems.
Response of cluster headache to psilocybin and LSD
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition to find out whether these patients had aborted attacks or reported remission period extension.
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse, and there was evidence for a beneficial effect of LSD on alcohol misuse.
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure, after adjusting for sociodemographics, other drug use and childhood depression.
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
A single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data, providing a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms.